Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Extends Timing of Tender Offer for Alere Preferred Stock

NEW YORK (GenomeWeb) – Abbott today announced that it is extending its previously announced cash tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at a price of $402 per share.

The offer is being made in connection to Abbott's $5.3 billion acquisition of Alere. Alere shareholders approved the acquisition in July.

The tender offer is being extended to allow additional time for the consummation of the deal, Abbott said.

The offer had been scheduled to expire at 11:59 p.m. EDT on Aug 11. It will now expire at 11:59 p.m. EDT on Aug. 31.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.